Kaitlyn Landis, PA
Physician Assistant · Knoxville, TNNPI 1396412391
Payments from drug & device makers
Across 304 payments — averaging $27.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$946
- Lilly USA, LLC$884
- Cequr Corporation$856
- Dexcom, Inc.$754
- Amgen$595
- Insulet Corporation$515
- plus $4K from 35 others
What the payments were for
- Food & beverage$8,20099%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 31 | $946 |
| Lilly USA, LLC | 51 | $884 |
| Cequr Corporation | 2 | $856 |
| Dexcom, Inc. | 37 | $754 |
| Amgen(2 entities) | 27 | $595 |
| Insulet Corporation | 20 | $515 |
| Xeris Pharmaceuticals, Inc. | 19 | $507 |
| BETA Bionics, Inc. | 13 | $383 |
| Sequel Med Tech, LLC | 4 | $237 |
| Sanofi-aventis U.S. LLC | 9 | $203 |
| Axsome Therapeutics, Inc. | 2 | $189 |
| Ascendis Pharma Endocrinology Inc | 5 | $180 |
| Radius Health, Inc. | 7 | $178 |
| Boehringer Ingelheim | 8 | $126 |
| Abbott | 7 | $125 |
| Corcept Therapeutics | 6 | $125 |
| Novartis | 6 | $124 |
| Tandem Diabetes Care, Inc. | 3 | $123 |
| Bayer | 7 | $123 |
| GSK | 1 | $121 |
| AbbVie | 1 | $112 |
| Medtronic | 4 | $111 |
| Averitas Pharma Inc. | 1 | $100 |
| Amneal Pharmaceuticals LLC | 5 | $76 |
| Esperion Therapeutics, Inc. | 3 | $63 |
| Neurocrine Biosciences, Inc. | 2 | $55 |
| AstraZeneca | 3 | $52 |
| Ascensia Diabetes Care US Inc. | 2 | $48 |
| Amphastar Pharmaceuticals, Inc. | 3 | $44 |
| Chiesi USA, Inc. | 2 | $41 |
| Intra-sana Laboratories | 2 | $38 |
| Tolmar, Inc. | 2 | $32 |
| Sanofi US Services Inc. | 1 | $25 |
| Sandoz | 1 | $24 |
| Merck | 1 | $21 |
| Antares Pharma, Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Echosens North America, Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,245 in reported general payments places this provider in the 95th percentile of 2,404 physician assistant providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 175 | $308,680 |
| MounjaroTirzepatide | 169 | $248,629 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 107 | $149,994 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 59 | $108,206 |
| JardianceEmpagliflozin | 99 | $100,635 |
| TrulicityDulaglutide | 62 | $96,473 |
| Tresiba Flextouch U-200Insulin Degludec | 69 | $85,393 |
| FarxigaDapagliflozin Propanediol | 62 | $64,821 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $57,864 |
| RybelsusSemaglutide | 39 | $51,346 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 21 | $43,860 |
| Tresiba Flextouch U-100Insulin Degludec | 61 | $33,290 |
| Repatha SureclickEvolocumab | 27 | $19,935 |
| ProliaDenosumab | 11 | $18,843 |
| Xigduo XrDapaglifloz Propaned/Metformin | 12 | $17,636 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $946 | $362,791228 claims |
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $884 | $346,535242 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $203 | $149,994107 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $126 | $144,495120 claims |
| AstraZenecaFarxiga | $52 | $64,82162 claims |
| AmgenProlia | $595 | $18,84311 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $76 | $4,087197 claims |
| AbbVieSynthroid | $112 | $2,17930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,404 physician assistant providers in Tennessee.
Other physician assistant in Knoxville
- Lindsey NixKnoxville$576K
- Katherine RunyanKnoxville$156K
- Kevin BlazerKnoxville$20K
- Meghan ShotwellKnoxville$18K
- Timothy VanceKnoxville$13K
- Danielle WarrenKnoxville$11K
- Anna KerseySavannah$399K
- Jason HenryNashville$329K
- Brie ChandlerNashville$317K
- Loree EasleyBartlett$209K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.